US President Donald Trump has praised Prime Minister Narendra Modi for efforts to combat illicit opium poppy cultivation and reinforce supply chain integrity, even as his administration identified India among 23 major drug transit or illicit drug-producing countries for fiscal year 2027. The presidential determination, submitted to Congress on 15 September and released in a media note on 16 September, sets out Washington's annual assessment of drug production, trafficking, and international cooperation.

What the Determination Says About India

Trump's statement on India was explicitly positive. 'I welcome Prime Minister Modi and the Government of India's efforts to address illicit opium poppy cultivation and bolster supply chain integrity,' he said, adding that he looked forward to 'continued cooperation through the United States-India Drug Policy Framework.'

Crucially, India was not among the four countries separately designated as having 'failed demonstrably' to meet their international counterdrug obligations during the previous 12 months. The determination itself underscores that inclusion on the broader list is not a verdict on a government's performance: 'A country's presence on the foregoing list is not necessarily a reflection of its government's current counterdrug efforts, or coordination with the United States,' the document states.

The Broader Country List and Who Failed

Alongside India, the 23-nation list includes China, Pakistan, Afghanistan, Mexico, and Colombia, among others. Countries placed on this list qualify under statutory definitions in the Foreign Assistance Act of 1961, which allows geographic, commercial, or economic factors — not just weak enforcement — to trigger inclusion.

Trump separately designated Afghanistan, Bolivia, Myanmar (referred to as Burma in the document), and Colombia as countries that had failed demonstrably to make substantial counterdrug efforts. He also determined that US assistance to Bolivia, Myanmar, and Colombia was 'vital to American national interests.' Notably, Venezuela was removed from the 'failed demonstrably' category, with Trump citing cooperation with its interim government and expressing expectation of continued, measurable progress.

Sharp Words for China, Canada, and Mexico

The document's treatment of India contrasted sharply with the tone directed at China, Canada, and Mexico. Trump accused China of remaining the world's largest producer of precursor chemicals used to manufacture fentanyl, methamphetamine, and other synthetic drugs. He said he had raised the issue directly with Chinese President Xi Jinping, and acknowledged that Beijing introduced licensing requirements last year for companies exporting designated precursor chemicals to North America at Trump's request — but said criminals continued to evade those controls through unregulated chemicals. Trump called on Beijing to expand chemical controls and strengthen cooperation on prosecutions.

On Canada, Trump alleged that clandestine laboratories were producing fentanyl and that precursor chemicals were transiting into the United States through Canadian territory. He urged action against those laboratories and criminal networks.

Mexican President Claudia Sheinbaum's administration received partial credit for greater drug seizures, dismantling of clandestine labs, and additional border security deployments — but Trump pressed Mexico to increase port inspections, deepen industry participation in supply chain security, and prosecute officials accused of aiding cartels.

India-US Drug Cooperation: The Bigger Picture

The United States-India Drug Policy Framework, referenced in Trump's statement, anchors bilateral cooperation on narcotics and supply chain security. India's inclusion on the statutory list has historical precedent and does not automatically trigger sanctions or aid restrictions. This is the first such determination under Trump's current term to explicitly commend India's counterdrug trajectory, signalling continued warmth in the bilateral relationship even as Washington presses harder on China and its immediate neighbours. How the two sides operationalise the Drug Policy Framework in the months ahead will be closely watched.